Illumina Accelerator invests in 7 genomics startups

By The Science Advisory Board staff writers

March 17, 2022 -- Illumina has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, U.K.

The latest investments included 4SR Biosciences, B4X, Cache DNA, CRISP-HR Therapeutics, NonExomics, Purpose Health, and Rethink Bio Private Limited. These startups focus on a variety of areas, including breakthrough therapeutics, diagnostics, DNA storage, mental wellness, and sustainable foods applications, according to the vendor.

Applications for the next global funding cycle are due by April 1. To learn more and apply, visit the accelerator site.

Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator...
Illumina Accelerator invests in 9 genomics startups
Illumina picked nine genomics companies to join the second global funding cycle of the Illumina Accelerator in the U.S. and U.K.
Illumina launches genomics incubator in China
Illumina has partnered with investment firm Sequoia Capital China to launch a new collaboration designed to create an incubator for startup companies...
Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter